Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders

Thumbnail
Date
2002-03
ICR Author
Matutes, Estella
Author
Matutes, E
Type
Journal Article
Metadata
Show full item record
Abstract
Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative disorders. In addition to the diagnostic value, the expression of certain markers such as p53 or CD38 provides relevant prognostic information to the clinician. Beyond their diagnostic and prognostic value, immunological markers play a major role in the detection of minimal residual disease, enabling the clinician to estimate more accurately the response to chemotherapy. Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed.
URI
https://repository.icr.ac.uk/handle/internal/2782
DOI
https://doi.org/10.1136/jcp.55.3.180
Collections
  • Clinical Studies
  • Molecular Pathology
Research team
Molecular Haematology (including Cytogenetics Group and Cell Markers)
Language
eng
License start date
2002-03
Citation
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 pp. 180 - 183

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.